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Abstract: Due to the high virulence of the SARS-CoV-2 virus, the infection rate in the community has led to a state of 
pandemic, leading to the introduction of new emergency measures all over the world. With the aim of controlling and 
preventing the SARS-CoV-2 viral epidemic, the health institutions performing medically assisted reproduction (MAR) 
suspended any new MAR treatments in order to reduce the burden on the health care system and implement current 
social distancing recommendations. Considering the favorable epidemiological situation in Croatia, our perspective is 
that it is time to conceive, plan and bring forth guidelines for restarting work in MAR centres, taking into account the 
selection of patients and organization of good laboratory and clinical practices with emphasis on the safety of patients 
and health workers. In regard to epidemiological knowledge, it is important to establish the reorganization of work in 
MAR centres including epidemiological measures of reducing unnecessary stays in closed spaces, the usage of 
protective gear by patients and health workers and disinfection of the working spaces and equipment. 
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INTRODUCTION 
The world is facing a new viral pandemic, Coronavirus 
Disease 2019 (COVID-19), that has spread quickly 
owing to its rapid community transmission, high 
virulence and sustained surface viability. Many 
infected and contagious individuals may only have 
mild symptoms, including fever, or, more rarely, they 
may be asymptomatic. COVID-19 is a respiratory 
illness caused by the novel coronavirus Severe Acute 
Respiratory Syndrome SARS-CoV-2, a single-stranded 
RNA virus. The term “COVID-19” is used to represent 
the viral respiratory disease and “coronavirus” to 
represent the SARS-CoV-2 virus.
1
 
Living and operating in a society where COVID-19 
exists is becoming a reality for many. Data suggest that 
COVID-19 will remain a factor to be managed in our 
lives and practices for a prolonged period of time. The 
ultimate response to this pandemic may rely on the 
development of a vaccine that prevents COVID-19, or 
of effective treatments, or both. 
As the COVID-19 pandemic is stabilizing, the return to 
normal daily life will also see the need to restart the 
provision of medically assisted reproduction (MAR) 
treatments.
2
 Infertility is a disease, and once the risk of 
SARS-CoV-2/COVID-19 infection has decreased, all 
assisted reproductive technology (ART) treatments can 
be restarted for any clinical indication. However, 
vigilance and measured steps must be taken for safe 
practice and to minimize the risks related to SARS-
CoV-2/COVID-19-positive patients or staff during 
treatment. 
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DISCUSSION 
Croatian Society of Clinical Embryologists consensus 
regarding IVF laboratory work and safety 
To avoid the consequences of SARS-CoV-2/COVID-
19 infection on IVF laboratory work, at a meeting on 
27th April 2020, Croatian Society of Clinical 
Embryology members considered the following topics 




Two main methods are used for the detection of virus 
infection: molecular (direct) and serological (indirect) 
method.
3
 The molecular method is based on the 
isolation of SARS-CoV-2 RNA from a nasopharyngeal 
swab and throat swab and the amplification of a few 
virus-specific genes (2-4) with RT-qPCR. While it is 
an expensive and time-consuming method, RT-qPCR 
tests are highly specific with low probability of false 
positives, but false negatives can occur if the sample 
contains insufficient quantities of the virus for 
successful amplification and detection. The amount of 
virus in a swab is likely to vary between patients, 
sample location (nasal, throat or sputum) and over time 
as the infection progresses. 
Instead of detecting viral genetic material, serological 
tests target the immune response of the infected person, 
looking out specifically for antibodies against the 
virus.
4
 These tests are cheap and fast. The problem 
with these tests is that antibodies only develop several 
weeks after an infection, which means that antibody-
based tests might miss asymptomatic cases or people in 
the earliest stage of the disease. Most serological tests 
are in the research stage of development and need 
further validation to determine their accuracy and 
reliability.  
As RT-qPCR looks for viral RNA, it will give a 
positive test result only if there is an ongoing infection. 
On the other hand, antibodies can persist for months or 




Disinfection and disinfectants 
In order to protect patients, their reproductive cells, 
embryos and embryologists who treat them, it is 
important to follow the basic disinfection and 
protection steps before entering the lab, in the lab, and 
after leaving the lab:  
1. Hand washing before putting on protective 
equipment.  
2. Disinfection of work surfaces before work.  
3. Disinfection of work surfaces between each 
patient.  
4. Disinfection of work surfaces and work 
incubators at the end of a working day.  
5. Disinfection of all items brought in and out of 
the lab. 
6. All paper required in the lab should be in easy-
to-disinfect plastic liners. 
7. Disinfection of incoming media vials (before 
first refrigerating and after each media 
preparation) and packaging of consumables 
before entering into the laboratory.  
8. Regular disinfection of incubators, cryo buckets, 
tweezers, pipettors, markers etc. 
Disinfectants with proven anti-enveloped viral activity 
should be used exactly according to the instructions for 
use: contact time, dilution and shelf life of concentrates 
and diluted solutions.  
Comparison of the genetic characteristics of SARS-
CoV-2 and Middle East respiratory syndrome 
coronavirus (MERS-CoV) suggests that SARS-CoV-2 
is susceptible to active compounds in disinfectants that 
have been shown to be active against other enveloped 
viruses.
5
 Effective disinfectants are those which have 
any of the following active compounds: sodium 
hypochlorite, bleach (0.1% -1%), ethanol (62-71%), 
hydrogen peroxide, phenolic compounds, 5% 
chlorinated agents, quaternary ammonium compounds. 
For disinfection of surfaces and incubators in the IVF 
laboratory, it is possible to use only disinfectants which 
have the quaternary ammonium compounds as active 
substance, such as Oosafe product lines. 
Air and space disinfection is possible with ultraviolet 
light (UV-C spectrum, about 250 nm).
6
 Ultraviolet 
radiation inactivates the nucleic acid of the virus (in 
this case ssRNA, which is the most susceptible to the 
UV radiation of all nucleic acids). The energy required 
for inactivation of the viral ssRNA is 1.32-3.20 mJ/cm
2
 
with lower energy required when the room humidity is 
lower. If the MAR centre decides to use UV 
disinfection of air and space, the previous chemical 
surface disinfection as well as the necessary 
precautions and additional training for the employees 
should be taken into account. 
 
 
Procedure for MAR laboratory staff members  
Triage questionnaire regarding health status, symptoms 
and lifestyle of all clinic team members two weeks 
prior to the start of all MAR laboratory activities 
(Figure 1), and the ART triage questionnaire 
(Appendix 1) for staff and patients when making 




Subdivision of the laboratory staff into mini-teams (1 
embryologist + 1 laboratory technician or 2 technicians 
in the case of more andrology procedures, such as 
semen cryopreservation) with minimum interaction 
among them is recommended. 
Mini-teams should work according to a rotating 
schedule every two weeks or a daily-based shift with 
the use of all necessary protective clothing (masks, 
disposable gloves and coats). If the teams split into  
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Figure 1. Staff triage (ESHRE guidance on recommending ART treatments, document prepared by the ESHRE COVID-19 Working Group, 
published on the ESHRE website, date of publication: 23/04/2020) 
 
 
daily-based shifts, there should be one hour between 
the shifts when the laboratory should be cleaned. 
To follow epidemiological measures, it is important to 
reduce unnecessary visits and embryologist/laboratory 
 
 
Appendix 1. ART triage questionnaire (ESHRE guidance on 
recommending ART treatments, Document prepared by the 
ESHRE COVID-19 Working Group, Published on the ESHRE 
website, Date of publication: 23/04/2020) 
 
technician-patient contact (e-mail or telephone). Also, 
it is important to restrict access for partners and 
accompanying persons not needed for procedures, 
possibly redesign waiting rooms to guarantee 
appropriate distancing. 
Appointments should be managed according to the 
specific timetables, and the number of patients in the 
waiting rooms should be limited. Also, there should be 
limited number of staff members in the transfer room 
(embryologist, gynecologist, nurse) with the patient.  
 
 
SARS-CoV-2 - The presence of virus in semen and 
testicular tissue 
Considering the evidence that novel SARS-CoV-2 can 
cause more than the respiratory symptoms 
characteristic for the coronavirus family, and especially 
due to its structural similarity to the previous SARS-
CoV-1, there are concerns that the infection could also 
affect the male reproductive system. 
SARS-CoV-1 has been associated with defects in 
spermatogenesis, testicular damage and inflammation, 
but it is still a matter of debate whether the virus is 
present in the tissue and whether the damage is caused 
directly by virus cell/tissue binding or by the immune 
system reaction.
7
 SARS-CoV-2 uses the same receptor 
angiotensin-converting enzyme 2 (ACE2) for cell entry 
as SARS-CoV-1. There are several studies about the 
expression pattern of ACE2 in human testis. Fan et al.
8
 
used RNA and protein expression data available online 
and found strong expression of ACE2 in testicular 
tissue. Furthermore, Wang et al.
9
 analyzed ACE2 at 
single-cell transcriptome level and found that it is 
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primarily expressed in spermatogonia and Leydig and 
Sertoli cells. Early spermatocytes, late spermatocytes, 
spermatids and other somatic cells had very low 
expression levels of ACE2.  The expression of 
transmembrane serine protease 2 (TMPRSS2) which 
enables S protein priming on the SARS-CoV-2 
envelope was also analyzed. TMPRSS2 expression was 
concentrated in spermatogonia and spermatids. 
Additionally, they found that ACE2-positive 
spermatogonia express a higher number of genes 
associated with viral reproduction and transmission, 
and a lower number of genes related to 
spermatogenesis compared with ACE2-negative 
spermatogonia. These studies suggest that there is 
theoretically a potential for viral binding and 
replication in testicular tissue, which could cause tissue 
damage, impairment of testicular function and 
potentially sexual transmission of the virus. It is 
important to note that there is one study with 
contradictory results, according to which the 
expression of ACE2 and TMPRSS2 in testicular tissue 
is very low, their co-expression is very rare and 
therefore virus binding and testicular infection is 
unlikely.
10
 There is no evidence of SARS-CoV-2 testis 
infection so far. Only one tissue sample from patients 




Viral RNA has been detected in feces and rarely in 
blood and urine. The studies published so far did not 
detect SARS-CoV-2 in semen. A total of 47 semen 
samples from patients with mainly mild to moderate 
symptoms have been tested. At the time of testing, 12 
patients were in the recovery phase (11 patients with a 
negative, one patient with a positive swab), 34 patients 
approximately one month from a positive swab, one 
patient eight days after a positive swab.
12
 
The above-mentioned studies are the first studies of 
SARS-CoV-2 related to male reproductive system. 
They have been conducted with certain limitations. 
Studies did not include larger sample size, patients with 
more severe symptoms and at an earlier phase of 
infection. More research is needed to elucidate the 
impact of the SARS-CoV-2 on the male reproductive 
system and until then, caution is recommended during 
semen and testicular tissue processing. 
A semen sample should be collected at home and the 
patients should deliver the sample to the laboratory 
within one hour of ejaculation in order to minimize 
their time spent at the fertility centre. If the patients are 
unable to collect the sample at home or bring it within 
one hour, the sample may be collected in a collection 
room that is thoroughly disinfected after each patient. 




The semen sample to be used in the in vitro fertilization 
treatment should be processed on a density gradient 
with an additional swim-up step. The addition of the 
layering culture medium to the pellet from the density 
gradient is an additional step in the purification of the 
sample.
14
 This kind of the semen preparation of the 
HIV positive patients has been shown to remove more 
than 99% of viral particles from the sample.
15
 The 
samples can be processed by a simple wash technique 
in the cases where a small number of sperm is present 
in the sample (severe oligoasthenozoospermia, 
testicular tissue) as they are not suitable for purification 
on a density gradient.
16
 No cases of viral transmission 
have been reported in the literature following the use of 





Follicular aspirate, oocytes and Covid-19 – viral 
presence and isolation procedure 
Recent research on the topic of oocyte isolation in time 
of the COVID-19 pandemic is virtually non-existent. It 
is important to determine the presence of viral SARS-
CoV-2 particles in follicular aspirate after oocyte 
retrieval in order to develop safe protocols for oocyte 
isolation to protect the staff and resolve issues 
concerning viral presence in oocyte culture. There are 
various confounding factors in recent research that can 
affect the use of results for developing protocols that 
include: small study samples, sampling patients after 
recovery from the infection, or age not suitable for 
reproduction. 
Since there is an absence of direct proof of the presence 
of SARS-CoV-2 particles in the follicular aspirate, an 
analysis of available literature concerning viral entry 
pathways in the cells of the female reproductive system 
has been conducted.   
A team of experts have analyzed 10 vaginal swabs 
from postmenopausal women in China after they 
recovered from COVID-19, and the swabs were sterile, 
which led to the conclusion that no viral particles are 
present in vaginal secretion.18 It is an important fact 
for performing an oocyte retrieval as regards the safety 
of medical staff, and it is also possible to exclude the 
contamination of follicular fluid with the viral particles 
via transvaginal ultrasound probe or punction. 
Research has shown that the ACE2 is an important cell 
receptor for SARS-CoV-2 viral particles and, in 
cooperation with TMPRSS2, which cleaves the S 
protein from the viral envelope, it enables viral 
invasion of the cell.   
Having that in mind, it was crucial to establish the 
presence of ACE2 and TMPRSS2 in tissues of human 
reproductive system. Ectocervix, endometrium and 
ovaries do express ACE2 receptors in cellular 
membranes. In addition, ACE2 expression has been 
confirmed in the entire process of ovarian 
folliculogenesis, from primordial to antral follicles, and 
the expression is amplified when under gonadotropin 
stimulation protocol. ACE2 is indirectly correlated to 
oocyte in vivo maturation. TMPRSS2 is somewhat less 
expressed and does not play an important role in the 
female reproductive system as it does in the male 
reproductive system, where it is a key factor for 
prostate cancer development. Despite of the receptor 
presence, SARS-CoV-2 particles have not been found 
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in the female reproductive system so far.
18
 
Concerning similarities in SARS-CoV-1 and SARS-
CoV-2 structure, a comparison was made regarding 
their presence in the female reproductive organs. A 
research showed that women deceased from SARS-
CoV-1 infection did not have viral particles in their 
reproductive organs.  
An important case study showed that it is possible to 
conclude that the virus can infect a fetus in utero, but 
the pathway of the infection is still unknown.
19
 
Also, since ACE2 receptors are abundantly present in 
the vascular endothelium, it is acceptable to presume 
an increased risk when performing ovarian puncture 
procedures since follicles are enveloped in a network of 
fine blood vessels that can possibly be a source of viral 
contamination for follicular fluid and pose a health risk 
for medical and laboratory staff. Undoubtedly, 
regulation of ACE2 is disturbed with gonadotropin 
stimulation and can, if combined with COVID-19, lead 
to pathophysiological changes in ovaries, multiplying 




Considering all the presented information, it is 
impossible to be sure of viral presence in follicular 
aspirate and to assess the risk of being affected with 
SARS-CoV-2 while performing oocyte isolation. It is 
imperative that the procedure is done with extra care in 
applying safety measures for all staff and all patients 
that are undergoing ART procedures. 
European Society for Human Reproduction (ESHRE) 
guidelines
21
 for performing oocyte retrieval 
recommend standard safety protocols and disinfecting 
measures and include fast disposal of the follicular 
fluids in special containers that are removed from the 
laboratory premises immediately after the procedure. It 
is also important to separate patient procedures by at 
least an hour in order to thoroughly clean and disinfect 
all surfaces and allow for air filtration to remove any 
potential contaminants of the air. 
 
 
In vitro fertilization technique, cell culture and 
COVID-19 
To minimize the risk of SARS-CoV-2/COVID-19 
infection during oocyte fertilization, it is recommended 
that the intracytoplasmic sperm injection (ICSI) 
technique is applied. At the time of oocyte retrieval, the 
virus may be in the follicular fluid, and thus may attach 
to granulosa cells surrounding the oocyte.  Before the 
ICSI procedure, these cells are removed enzymatically 
and mechanically from the oocyte. Therefore, the ICSI 
procedure reduces the chances of possible viral 
infection. Regardless of viral status, it is recommended 
that these precautions take place for each patient as part 
of good laboratory practice.
22
 Devaux et al.
23
 showed in 
17 women positive for Hepatitis C Virus (HCV) that 
viral RNA was detected by PCR in 89% of follicular 
fluid samples. After denuding the oocytes of granulosa 
cells, inseminating the oocytes via ICSI, washing the 
oocytes and embryos and refreshing the media during 
culture, the viral load became undetectable, irrespective 
of the original follicular fluid status. Therefore, the 
authors concluded that follicular fluid must be 
considered as potentially infected, but all oocytes can 
be inseminated by ICSI resulting in virus-free embryos 
in culture. 
To reduce the spread of potential infection in cell 
culture, the use of individual oocyte/embryo culture 
under paraffin oil is recommended. The workspace, 
laminar hood, and inverted microscope stage need to be 
disinfected (e.g. Oosafe) and cleaned with sterile water 
after each procedure. 




• Use personal protective equipment (laboratory coat 




• Use micropipette tips with filter 
• Turn on laminar hood air flow minimum 10 min 
before work 
• Disinfect the laminar hood working area (e.g. 
Oosafe), followed by cleaning with sterile water 
 
 
Cryopreservation of biological samples and SARS-
CoV-2 
SARS-CoV-2 is a RNA coronavirus with the ability of 
surviving low temperatures and reactivation after the 
stable conditions in culture media are retained.
25
 
Extreme caution is advised when freezing and thawing 
the biological samples (semen, testicular tissue, oocytes 
and embryos) because of possible contamination with 
viral particles.
26
 Since oocytes and embryos do not 
have the necessary receptors for SARS-CoV-2 to attach 
to them, there is no risk of viral integration in the  host 
genome, but there is a possible danger of transmission 
of the virus through the culture media or liquid 
nitrogen to the patients or medical staff.
27
 To lower the 
risk of virus transmission through contaminated culture 
media, it is necessary to heavily dilute the samples 
(oocytes, embryos) before the freezing procedure. 
Because of the possibility of contamination of liquid 
nitrogen with the SARS-CoV-2 virus, and thus 
contamination of biological sample, avoiding any 
contact of biological sample and liquid nitrogen before 
the freezing procedure (slow freezing method or 
vitrification with the closed system) is advised.
28
 When 
freezing the semen samples or testicular tissue, it is 
necessary to follow the standard protocol with 
additional handling precautions (there is no direct 
contact between the sample and liquid nitrogen, 
because the sample is stored in closed cryogenic straws 
and cryogenic vials). 
Recommendations for handling biological material in 
the process of freezing/thawing during the SARS-CoV-
2 virus are: 
• Sterilization of the equipment (forceps, steel bath, 
cryogenic canes) 
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• Dilute the biological material before freezing 
procedure and after the thawing procedure 
(oocytes and embryos) 
• Usage of special tanks with liquid nitrogen just for 
the biological samples which are frozen with open 
vitrification system in the time of pandemic. If the 
samples are frozen with the closed vitrification 




Management of patients positive for SARS-CoV-2 
virus during the IVF procedure 
Considering the fact that there is still no scientific 
evidence on different pathways of transmission of the 
virus, as well as on the impact of the virus on human 
gametes and embryos, we are obliged to ensure that 
measures are taken to prevent and control the spread of 
infection among our patients as well as among 
healthcare personnel participating in the procedures of 
medically assisted reproduction.
29, 30
 If the MAR centre 
does not meet the technical standards for safe 
epidemiological treatment prescribed in the treatment 
of COVID-19 positive patients
31
 (which includes a 
separate aspiration room with an associated separate 
IVF laboratory for COVID-19 positive patients only), 
we suggest the following: 
1. If symptoms occur and/or a patient tests positive 
for COVID-19 at an earlier stage of the 
procedure (before aspiration or embryo 
thawing): cancel and postpone the treatment. 
2. If symptoms occur after aspiration, and during 
embryo cultivation, confirm the infection with a 
test: freeze all, with special care on safe 
cryopreservation. 
If symptoms occur and we have a positive test before 
aspiration, but the patient is at high risk (life-
threatening) of ovarian hyperstimulation (OHSS) or is 
an oncofertility patient, in those exceptional cases, 
aspiration of oocytes will be performed in a specially 
equipped and separate aspiration room intended for use 
with COVID-19 positive patients, where all 
epidemiological measures are respected: special 
procedure for putting on and removing PPE (e.g., 
personal protective equipment: isolation gowns and 
coveralls, surgical cap, surgical mask, goggles, face 
shield, two pairs of nitrile gloves), separate entrance 
and exit, ventilation area before undressing, tent for 
equipment removal. 
After the aspiration, additional three hours are required 
in this area to cryopreserve the oocytes, but only if 
there is an associated separated IVF laboratory for 
COVID-19 positive patients (laminar flow hood with 
heated stage, stereo microscope, a CO2 incubator with 
gas mixture supply, portable liquid nitrogen container, 
cooling rack). 
Unfortunately, no IVF laboratory in Croatia meets the 
technical standards prescribed in the treatment of 
COVID-19-positive patients and we would not be able 
to complete the procedure for such patients. The 
procedure of aspiration of oocytes in a specially 
equipped and separate aspiration room intended for use 
with COVID-19 positive patients requires a significant 
financial investment, but it is the only way to safely 
handle these conditions and quality storage of 
biological material that is extremely sensitive to 
external conditions (temperature, CO2, pH). 
 
 
Recommendation regarding laboratory work safety 
Guidelines for reducing the risk of SARS-CoV-2 
transmission during medically assisted reproduction 
treatments in homologous procedures (non-donor 
fertilization): 
• Planning MAR procedures exclusively with 
patients that have been proven healthy in centres 
that can adjust their work to the new 
circumstances. 
• IVF laboratory preparation for restarting work 
includes cleaning and sterilization of incubators, 
cleaning of all equipment and working surfaces, 
walls, floors, doors and passages, as well as 
purchasing media and materials. 
• Cleaning of the laboratory according to prescribed 
standard operative procedures (SOP), but with 
intensified frequency after every patient or work 
with a particular biological sample. Recommended 
intervals between two oocyte aspirations is a 
minimum of 1 hour needed for the adequate 
finishing of procedures for one couple and 
preparation for the next couple. 
• After restarting work, all IVF laboratories need to 
work in the regime of high vigilance according to 
ESHRE21 and EDQM (European Directorate for 
the Quality of Medicines)
32
 guidelines in order to 
obtain quality and safety working with tissues, 
cells and organs. 
• Health workers need to wear masks, caps, gloves 
and safety gowns covering the skin. 
• If there are two or more embryologists working in 
the laboratory, it is necessary to organize work in 
separate working hours; in other words, separation 
in two work teams (A and B) formed of a doctor 
gynecologist, a nurse and a clinical embryologist. 
In extreme cases when clinical embryologists need 
to go into quarantine/isolation, the patients are 
taken care of in a cooperative facility. 
• Clinical embryologists need to minimize their 
contact with the rest of the working staff and 
patients. If they need to communicate it is 
important to keep a distance of 2 meters while 
wearing a mandatory protective face mask. 
The handling of samples is based on guidelines without 
scientific evidence, but applied as precautionary 
measures:  
• Semen samples for MAR procedures are collected 
at home and brought by men with minimal time 
spent in the IVF facility. 
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• Sperm preparation technique with density-gradient 
followed by swim-up technique14 
• Additional oocyte washing after isolation from 
follicular fluid 
• ICSI (Intracytoplasmic Sperm Injection) is 
recommended for fertilization  
• Additional washing of embryos prior to embryo 
transfer in uterus  
• Additional washing of embryos after embryo 
thawing 
Considering the fact that there is still no scientific 
evidence on different pathways of transmission of the 
virus, as well as on the impact of the virus on human 
gametes and embryos, we are obliged to ensure that 
measures are taken to prevent and control the spread of 
infection among our patients as well as among 
healthcare personnel participating in the procedures of 
medically assisted reproduction. If the IVF centre does 
not meet the technical standards for safe 
epidemiological treatment prescribed in the treatment 
of Covid-19 positive patients (which includes a 
separate aspiration room with an associated IVF 
laboratory for Covid-19 positive patients only), we 
suggest the following: 
1. If symptoms occur and / or patient tests positive 
for Covid-19 at an earlier stage of the procedure 
(before aspiration or embryo thawing): cancel 
and postpone the treatment. 
2. If symptoms occur after aspiration, and during 
embryo cultivation, confirm the infection with a 





1. The triage of personnel and patients according to 
the questionnaire, with further COVID-19 
testing based on the triage. 
2. The method used for virus detection is RT-qPCR 
amplification. 
3. Both partners that are entering the IVF/ICSI 
treatment need to be tested for COVID-19 two 
days prior to follicle aspiration. Male partners in 
the intrauterine insemination (IUI) procedure, as 
well as female patients undergoing the frozen 
embryo transfer (FET) procedure need to be 
tested two days before the procedures. 
4. In cases of a positive COVID-19 test, the 
patients' treatment cycle is stopped.  
5. In cases of ovarian hyperstimulation syndrome 
and proven COVID-19 infection, follicle 
aspiration is done exclusively for the purpose of 
protecting the patients' health and not for in vitro 
procedure. Therefore, the follicular fluid is not 
delivered to the IVF laboratory, instead it is 
taken care of and disposed as prescribed.  
6. Considering it is still unclear how the infection 
can be transmitted, and testing may result in 
false negatives due to the inappropriate handling 
of swab specimens, all epidemiological 
guidelines and the Croatian Society for Human 
Reproduction guidelines (Croatian Society of 
Clinical Embryologists - Guidelines on the 
health epidemiological framework for 
implementation in medically assisted 
reproduction procedures during COVID-19 
pandemic regarding patients and medical health 
workers safety) are applied. 
7. If a female patient expresses COVID-19 
symptoms before the day of the embryo transfer, 
embryos are to be frozen in a closed type carrier 
according to standard procedure or stored in a 
separate cryotank. 
8. Embryologists are working in a two-team 
regime, organized for rotational work every two 
weeks, or in morning/afternoon shifts. A one-
hour interval between daily shifts is necessary 
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